
New clinical data on first-in-class METTL3 inhibitor
Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024. The Phase I clinical study… Read More















